Pharma Jobs

NEW RELEASES :- Pharmatimes

NHS backs delayed‑release treatment for cystinosis August 5, 2026
Decision expands options for eligible patients
John Pinching
Oblenio doses first patients in phase 1a autoimmune trial August 5, 2026
Study evaluates tri‑specific T cell engager LBL‑051
John Pinching
BeOne Medicines secures UK innovation passport for HCC therapy August 5, 2026
Designation supports accelerated access for investigational antibody
John Pinching
Sanofi’s MenQuadfi approved for EU infants August 4, 2026
EC expands use to protect youngest children
John Pinching
Qnovia licenses novel antimicrobial peptide August 4, 2026
New therapy aims to tackle antibiotic resistance
John Pinching
Polpharma Biologics gains FDA and EMA review acceptances August 3, 2026
Regulators assess PB016 vedolizumab biosimilar applications
John Pinching
Parsortix study shows promise for ADC target detection August 3, 2026
Researchers highlight minimally invasive monitoring potential
John Pinching
Vista trial begins dosing in precision cancer vaccine study July 30, 2026
First-in-human evaluation of infinitopes’ therapeutic platform
John Pinching
Lynavoy recommended for EU approval by the CHMP July 30, 2026
First IBAT inhibitor for PBC cholestatic pruritus
John Pinching
Atsena gains EMA orphan status for two gene therapies July 29, 2026
Designation supports pivotal trials for emerging candidates
John Pinching

NEW RELEASES :- Pharma Voice

Erica Schwartz confirmed as next CDC director August 6, 2026
Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief.
Kristin Jensen
What the AstraZeneca-BMS rumors reveal about pharma megamergers August 6, 2026
Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.
Kelly Bilodeau
FDA allows unique endpoint in rare disease study August 5, 2026
Global regulators are allowing the company to use hospitalization as the primary efficacy endpoint in its registration trial for a rare neuromuscular disorder.
Alexandra Pecci
Merck is pharma’s most patent-exposed company. Now it’s reinventing itself. August 5, 2026
Keytruda made Merck an oncology powerhouse, but as the patent cliff looms, its business development leader outlines what’s next.
Meagan Parrish
Three potential takeover targets in psychedelics August 4, 2026
Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.
Kelly Bilodeau
Trump has another tariff plan to reshore generic drug production. Will it work? August 3, 2026
The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic drug production.
Kelly Bilodeau
The future of oral drug delivery must be sustainable August 3, 2026
How Evonik is shaping more sustainable oral drug delivery through data and excipient innovation.
Lucas Cusin, Global Technical Marketing Manager, Oral Drug Delivery Solutions, Evonik & Thilo Krapfl, Head of Product Line Oral Drug Delivery Solutions, Evonik
Specialty pharma has an infrastructure problem, and IT can’t solve it alone August 3, 2026
Technology to enable the specialty patient journey is becoming IT's problem, but the fix isn't becoming the expert.
Danny Sigurdson, Founder and CEO, Courier Health
Why pharma’s record-setting M&A streak is so unique July 31, 2026
Early-stage candidates, mid-sized companies and of course, Chinese assets, are dominating the dealmaking picture this year.
Kelly Bilodeau
Genetic clues for cell therapy toxicities; Summit’s high-stakes FDA decision July 31, 2026
Researchers have pinpointed genes linked to dangerous CAR-T cell therapy side effects, and a predictions market weighs in on Summit’s closely-watched cancer drug.
PharmaVoice Staff

[wp-rss-aggregator feeds="pharmexec-com"]

[wp-rss-aggregator feeds="pharmiweb-com-articles"]

NHS backs delayed‑release treatment for cystinosis
Decision expands options for eligible patients
Oblenio doses first patients in phase 1a autoimmune trial
Study evaluates tri‑specific T cell engager LBL‑051
BeOne Medicines secures UK innovation passport for HCC therapy
Designation supports accelerated access for investigational antibody
Sanofi’s MenQuadfi approved for EU infants
EC expands use to protect youngest children
Qnovia licenses novel antimicrobial peptide
New therapy aims to tackle antibiotic resistance
Polpharma Biologics gains FDA and EMA review acceptances
Regulators assess PB016 vedolizumab biosimilar applications
Parsortix study shows promise for ADC target detection
Researchers highlight minimally invasive monitoring potential
Vista trial begins dosing in precision cancer vaccine study
First-in-human evaluation of infinitopes’ therapeutic platform
Lynavoy recommended for EU approval by the CHMP
First IBAT inhibitor for PBC cholestatic pruritus
Atsena gains EMA orphan status for two gene therapies
Designation supports pivotal trials for emerging candidates

GMP and Quality

Non-conformances in Pharmaceutical Laboratories

Pharma VedMay 8, 2024

Pharmaceutical quality control laboratories are the guardians of public health. Through meticulous testing of raw materials, in-process materials, and finished products, they ensure the safety and efficacy of medications. However, nonconformances can arise...